With the planned IPO for its Singapore subsidiary, JLS will go onto further reduce its net debt while continuing additional capex, says Siddharth Sedani of Anand Rathi Shares and Stock Brokers.from Moneycontrol Latest News https://ift.tt/2PNHVEq
Friday 31 August 2018
Buy Jubilant Life Sciences, target Rs 1,040: Siddharth Sedani
With the planned IPO for its Singapore subsidiary, JLS will go onto further reduce its net debt while continuing additional capex, says Siddharth Sedani of Anand Rathi Shares and Stock Brokers.from Moneycontrol Latest News https://ift.tt/2PNHVEq
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment